Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» earnings
earnings
Zacks Industry Outlook Highlights Eli Lilly, J&J, Novo Nordisk, Novartis and AstraZeneca
Zacks Industry Outlook Highlights Eli Lilly, J&J, Novo Nordisk, Novartis and AstraZeneca
Yahoo/Zacks.com
earnings
Eli Lilly
JNJ
Novo Nordisk
Novartis
AstraZeneca
Flag link:
Obesity, diabetes drugs push Novo Nordisk and Eli Lilly to front of pharma's growth pack in Q2
Obesity, diabetes drugs push Novo Nordisk and Eli Lilly to front of pharma's growth pack in Q2
Fierce Pharma
Novo Nordisk
Eli Lilly
obesity
diabetes
earnings
Flag link:
3 Biotech Stocks Poised to Beat Q2 Earnings Estimates
3 Biotech Stocks Poised to Beat Q2 Earnings Estimates
Yahoo/Zacks.com
earnings
Legend Biotech
Kodiak Sciences
Galera Therapeutics
Flag link:
Amylyx ALS drug sales tick higher after fast US launch
Amylyx ALS drug sales tick higher after fast US launch
BioPharma Dive
Amylx
earnings
ALS
Flag link:
Why Shares of Deciphera Pharmaceuticals Rose This Week
Why Shares of Deciphera Pharmaceuticals Rose This Week
Motley Fool
Deciphera
earnings
Qinlock
GIST
Flag link:
Illumina Slides After Slashing Full-Year Forecast
Illumina Slides After Slashing Full-Year Forecast
Yahoo/Bloomberg
Illumina
diagnostics
earnings
Flag link:
Why 23andMe Holding Stock Plummeted by 13% Today
Why 23andMe Holding Stock Plummeted by 13% Today
Motley Fool
earnings
23andMe
diagnostics
genetics
Flag link:
Novavax Posts Surprise Q2 Profit, Hinges Hopes on Updated COVID Shot
Novavax Posts Surprise Q2 Profit, Hinges Hopes on Updated COVID Shot
BioSpace
Novavax
earnings
COVID-19
Flag link:
Eli Lilly raises full-year guidance as Mounjaro, other drugs drive second-quarter profit up 85%
Eli Lilly raises full-year guidance as Mounjaro, other drugs drive second-quarter profit up 85%
CNBC
Eli Lilly
earnings
Mounjaro
Flag link:
FibroGen Looks to Regroup After Rocky Q2 Results, Ongoing Challenges
FibroGen Looks to Regroup After Rocky Q2 Results, Ongoing Challenges
BioSpace
FibroGen
earnings
Flag link:
Bayer ends respiratory distress drug development in latest phase 2 cleanout
Bayer ends respiratory distress drug development in latest phase 2 cleanout
Fierce Pharma
Bayer
adrenomedullin pegol
earnings
ARDS
Flag link:
BioNTech sticks with COVID vaccine outlook amid sharp revenue declines
BioNTech sticks with COVID vaccine outlook amid sharp revenue declines
Medical Marketing and Media
BioNTech
earnings
COVID-19
Flag link:
Bausch + Lomb's Saunders doesn't expect more big deals in the near term
Bausch + Lomb's Saunders doesn't expect more big deals in the near term
Reuters
Bausch + Lomb
Pharma CEOs
Brent Saunders
earnings
M&A
Flag link:
Gilead quarterly profit falls on COVID sales drop, legal settlement charge
Gilead quarterly profit falls on COVID sales drop, legal settlement charge
Reuters
Gilead Sciences
earnings
Flag link:
BD prepares for relaunch of Alaris pump, raises revenue forecast
BD prepares for relaunch of Alaris pump, raises revenue forecast
Medtech Dive
Becton Dickinson
Medtech
earnings
Alaris pump
infusion pumps
Flag link:
Moderna, Regeneron post solid earnings, eye a strong finish to 2023
Moderna, Regeneron post solid earnings, eye a strong finish to 2023
Medical Marketing and Media
earnings
Moderna Therapeutics
Regeneron
Flag link:
Filings signal: Despite Covid losses, pharma earnings are promising
Filings signal: Despite Covid losses, pharma earnings are promising
Clinical Trials Arena
Takeda
AstraZeneca
Roche
earnings
COVID-19
Flag link:
Vertex Pharma raises full-year revenue forecast on cystic fibrosis treatment strength
Vertex Pharma raises full-year revenue forecast on cystic fibrosis treatment strength
Yahoo/Reuters
Vertex Pharmaceuticals
cystic fibrosis
earnings
Flag link:
CVS Health Profits Drop To $1.9 Billion As Restructuring Costs Take Hold
CVS Health Profits Drop To $1.9 Billion As Restructuring Costs Take Hold
Forbes
CVS Health
earnings
restructuring
Flag link:
Boehringer Ingelheim posts more Jardiance growth as potential US kidney disease approval nears
Boehringer Ingelheim posts more Jardiance growth as potential US kidney disease approval nears
Fierce Pharma
Boehringer Ingelheim
Jardiance
diabetes
earnings
Flag link:
Pages
1
2
3
4
5
6
7
8
9
…
next ›
last »